Genomic and Proteomic Network for Premature Birth Resea*

该提案构成了犹他州大学申请NICHD基因组和蛋白质组 早产研究网络。犹他州大学有许多独特的优势， 使其成为网络的理想中心。这些措施包括：多中心研究生产力 合作研究：犹他州大学母胎医学部（MFM） 在过去的五年中，他为超过15项多中心临床试验做出了重大贡献， NICHD/MFMU网络的领先招聘中心。超过12，000名犹他州患者 参加了最近完成的FASTER试验，占12- 中心试验。犹他州大学也参与了死产合作研究网络 以及全球妇女儿童健康研究网络。 二.早产：犹他州大学享有国际声誉，作为一个中心， 卓越的早产临床护理和研究。三、利用基因组技术的专门知识 研究早产的蛋白质组学技术：母胎医学部 发表了关于使用cDNA微阵列来鉴定具有劳动力特异性表达的基因， 还报道了子宫肌层中细胞因子多态性和自发性早产， 不同民族的人口。我们最近还报道了使用蛋白质组学的经验， 确定足月和早产潜在预测因子。四.生殖和医学遗传学： 犹他州独特的人口吸引了许多世界级的遗传学家来到这所大学。状态 the art艺术moleculary分子and clinical临床genetic遗传capabilities能力will be available提供to the Network网络.诉 大学/社区协同作用：犹他州的MFM专家拥有独特的临床和研究能力， 这种伙伴关系跨越了相互竞争的医疗保健系统， 临床研究六.招生策略：研究基础设施目前在 四个区域三级护理中心，已经并将继续允许犹他州大学成为 大型多中心试验的领先招募中心之一。

This proposal constitutesthe University of Utah application for the NICHD Genomic and Proteomic Network for PrematureBirth Research. The University of Utah has numerousunique strengths that make it an ideal center for the network. These include: I. Research Productivity in Multicenter Collaborative Studies: The University of Utah Maternal-Fetal Medicine (MFM) Division has made substantial contributions to over 15 multicenter clinical trials during the past five years and is a leading recruitment center for the NICHD/MFMU Network. Over 12,000 Utah patients were enrolled in the recently completed FASTER trial, accounting for almost 32% of subjects in the 12- center trial. The University of Utah also participates in the Stillbirth Collaborative Research Network and the Global Network for Women's and Children'sHealth Research. II. Premature Birth: The Universityof Utah enjoys international recognitionas a center of excellence for clinical care and research on premature birth. III.Expertise in the Use of Genomic and Proteomic Techniques to Study Premature Birth: The Maternal-Fetal Medicine Divisionhas published on the use of cDNA microarray to identify genes with labor-specific expression within myometrium and has also reported on cytokine polymorphisms and spontaneous preterm birth in various ethnic populations. We have also recently reported experience with the use of proteomics to identify potentialpredictors of term and preterm birth. IV. Reproductive and Medical Genetics: Utah's distinctpopulation has attracted numerousworld-class geneticists to the University. State of the art molecularand clinical genetic capabilities will be made availableto the Network. V. University / Community Synergy: MFM specialistsin Utah have a unique clinical and research partnership that crosses competing health care systems and affords universalaccess to patients for clinical research. VI. Proven Enrollment Strategy: Research infrastructure is currentlyin place at four regional tertiary care centers that has and will continue to allow the University of Utah to be among the leading recruitment centers for large multicenter trials.